Iovate claims challenged
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program forum recommends Iovate Health Sciences modify or discontinue some claims for its Cylaris and Rapid Slim SX weight-loss products in two May 16 decisions. WellNx Life Sciences, a competing supplement company, challenged Iovate's claims for both Cissus quadrangularis-containing products in the self-regulatory forum. ERSP determines Iovate provides reasonable basis for claims such as "contains proven, clinical-strength ingredients" but available public research does not support Iovate's "World's Strongest Weight-Loss Formula" or "World's Fastest Weight-Loss Solution" claims. ERSP cautions Iovate's "lose up to 32 lbs in 8 weeks" claim for Cylaris arguably qualifies as an inherently misleading statement under FTC's Red Flag Guide on weight-loss claims (1"The Tan Sheet" April 17, 2006, p. 10)...
You may also be interested in...
FTC “Disappointed” By Abundance Of Red Flag Weight-Loss Ads
FTC is considering what steps it will take in response to a "disappointing" run of advertisements containing "red flag" weight-loss claims by the print media in recent months, according to Richard Cleland, assistant director of the commission's Division of Advertising Practices
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.